Skip to main content
Premium Trial:

Request an Annual Quote

Amgen Layoffs

Amgen is laying off 380 people from its research and development division, reports Fierce Biotech. The layoffs will be mainly in the US, with 226 people being let go from the company's Thousand Oaks location, with others from Seattle, South San Francisco, Boston, and possibly in the UK. Fierce Biotech notes that while the layoffs represent 2 percent of the company's overall workforce, they are 6 percent of its R&D staff. "These are very targeted and strategic reductions so we can continue to allocate our R&D resources in a focused manner," says Amgen spokesperson Mary Klem, according to Reuters.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.